SUMMARY

Diseases, associated with a vast loss of function usually result from misguided wound healing or fibrogenesis. Yet, no causal therapy for fibrotic diseases in general exists. Ocular fibrosis displays an unmet medical need, including the scar formation on the cornea, leading to blindness. The team first developed a novel peptide-based anti-fibrotic therapy and showed its efficacy in a mouse model of corneal fibrosis. In the scope of this project, the team focuses on peptide optimizations as well as relevant assays regarding pharmacological evaluation of absorption, distribution, metabolism, excretion, toxicity and safety. If successful, the potentials of the peptide-based treatment for ocular and system medicine, especially pulmonary fibrosis, will be evaluated.

PROJECT GOALS

- Pharmacological evaluation of absorption, distribution, metabolism, excretion, toxicity parameters
- Validation in second animal model

LONG-TERM GOALS

- Licensing to industry or startup foundation
- Broaden treatment to other indications